VivoGenie Anti-Human PD-1 (Cemiplimab) - Fc Reduced Biosimilar (IVMB0479)
- SKU:
- IVMB0479
- Antibody Type:
- In Vivo Biosimilar
- Endotoxin Level:
- Low Endotoxin
- Applications:
- In Vivo
- Disease Area:
- Cancer Immunotherapy
- Disease Area:
- Autoimmune Diseases
Description
| Product Name: | Anti-Human PD-1 (Cemiplimab) |
| SKU: | IVMB0479 |
| Size: | 500 µg |
| Antibody Type: | Biosimilar Recombinant Human Monoclonal Antibody |
| Clone: | REGN2810 |
| Target: | PD-1 |
| Isotype: | Human IgG4κ |
| Host Species: | Human |
| Reactivity: | Human |
| Applications: | ELISA |
| Expression Host: | HEK-293 Cells |
| FC Effector Activity: | Muted |
| Synonyms: | CD279, PD1, REGN-2810, Anti-PD1, PDCD1 |
| Product Concentration: | ≥ 5.0 mg/ml |
| Purity: | ≥95% by SDS Page |
| Immunogen: | Human PD-1 |
| Endotoxin Level: | < 1.0 EU/mg as determined by the LAL method |
| Antigen Distribution: | PD-1 is expressed on activated T cells, B cells, a subset of thymocytes, macrophages, dendritic cells, and some tumor cells and is also retained in the intracellular compartments of regulatory T cells (Tregs). |
| Formulation: | This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. |
| Specificity: | This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Cemiplimab. This product is for research use only. Cemiplimab activity is directed against Human PD-1. |
| Additional Applications Reported In Literature: | ELISA WP IP FA FC |
PD-1 is a transmembrane protein in the CD28/CTLA-4 subfamily of the Ig superfamily1, 2. When stimulated via the T cell receptor (TCR), Tregs translocate PD-1 to the cell surface3. Programmed cell death 1 ligand 1 (PD-L1; CD274; B7H1) and programmed cell death 1 ligand 2 (PD-L2; CD273; B7DC) have been identified as PD-1 ligands1. PD-1 is co-expressed with PD-L1 on tumor cells and tumor-infiltrating antigen-presenting cells (APCs)2. Additionally, PD-1 is co-expressed with IL2RA on activated CD4+ T cells3.
PD-1 is an immune checkpoint receptor that suppresses cancer-specific immune responses4. Additionally, PD-1 acts as a T cell inhibitory receptor and plays a critical role in peripheral tolerance induction and autoimmune disease prevention as well as important roles in the survival of dendritic cells, macrophage phagocytosis, and tumor cell glycolysis2. PD-1 prevents uncontrolled T cell activity, leading to attenuation of T cell proliferation, cytokine production, and cytolytic activities. Additionally, the PD-1 pathway is a major mechanism of tumor immune evasion, and, as such, PD-1 is a target of cancer immunotherapy2.
Cemiplimab is a fully human, hinge-stabilized (S228P) high affinity anti-PD-1 antibody that potently blocks PD-1 interaction with PD-L1 and PD-L2 ligands and enhances human primary T-cell responses in vitro5. Cemiplimab was generated using VelocImmune knock-in mice immunized with recombinant human PD-1-mFc protein containing the PD-1 extracellular domain (amino acids 1-167) and the Fc portion of mouse IgG2a. Splenocyte-derived hybridomas were screened for human monoclonal antibody reactivity to recombinant human PD-1-hFc (extracellular domain of human PD-1 fused to human IgG1 Fc).
Cemiplimab is the first approved treatment in the United States and EU for patients with locally advanced or metastatic cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiotherapy6.
| Ligand/Receptor: | PD-1, CD279 |
| State of Matter: | Liquid |
| Regulatory Status: | Research Use Only (RUO). Non-Therapeutic. |
| Product Preparation: | Recombinant biosimilar antibodies are manufactured in an animal free facility using onlyin vitroprotein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. |
| Pathogen Testing: | To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. |
| Storage and Handling: | Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. |
| UniProt: | Q9UMF3 |
| Research Area: | Biosimilars |
Related Products
VivoGenie Anti-Human PD-1 (Cemiplimab) Biosimilar (IVMB0477)
VivoGenie Anti-Human PD-1 (Camrelizumab) - Fc Reduced Biosimilar (IVMB0545)
VivoGenie Anti-Human PD-1 (Pembrolizumab) - Fc Reduced Biosimilar (IVMB0483)
VivoGenie Anti-Human PD-1 (Sintilimab) - Fc Reduced Biosimilar (IVMB0535)
